Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate (vol 16, pg 888, 2010)

被引：1
|
作者：
Okeley, N. M.
Miyamoto, J. B.
Zhang, X.
Sanderson, R. J.
Benjamin, D. R.
Sievers, E. L.
机构：
来源：
CLINICAL CANCER RESEARCH | 2011年 / 17卷 / 16期
关键词：
D O I：
10.1158/1078-0432.CCR-11-1753
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：5524 / 5524
页数：1
相关论文
共 50 条
  • [41] An Anti-CD7 Antibody-Drug Conjugate Target Showing Potent Antitumor Activity for T-Lymphoblastic Leukemia (T-ALL)
    Wang, Shiqi
    Zhang, Ruyuan
    Zhong, Kunhong
    Guo, Wenhao
    Tong, Aiping
    BIOMOLECULES, 2024, 14 (01)
  • [42] Generation of the single chain antibody fragment conserves the idiotypic profile of the anti-CD30 monoclonal antibody HRS3. (vol 48, pg 497, 1998)
    Hombach, A
    Pohl, C
    Heuser, C
    Sircar, R
    Koch, D
    Diehl, V
    Abken, H
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1999, 50 (02) : 232 - 232
  • [43] NOVEL TREATMENT APPROACH FOR PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) PURE EMBRYONAL CARCINOMA WITH INTENSIVE INDUCTION AND CONSOLIDATION MARROW-ABLATIVE CHEMOTHERAPY FOLLOWED BY AN ANTI-CD30 ANTIBODY-DRUG CONJUGATE, WITHOUT IRRADIATION
    Abu Arja, Mohammad H.
    Conley, Suzanne E.
    AbdelBaki, Mohamed S.
    Osorio, Diana S.
    Coven, Scott
    Abu-Arja, Rolla T.
    Boue, Daniel
    Ginn, Kevin
    Leonard, Jeffrey
    Finlay, Jonathan L.
    NEURO-ONCOLOGY, 2018, 20 : 84 - 84
  • [44] RETRACTION: Prevention of carrageenan-induced pleurisy in mice by anti-CD30 ligand monoclonal antibody (Retraction of Vol 113, Pg 64, 2004)
    Di Paola, Rosanna
    Di Marco, Roberto
    Mazzon, Emanuela
    Genovese, Tiziana
    Bendtzen, Klaus
    Macri, Battesimo
    Nicoletti, Ferdinando
    Cuzzocrea, Salvatore
    CLINICAL IMMUNOLOGY, 2024, 262
  • [45] Comprehensive Middle-Down Mass Spectrometry Characterization of an Antibody-Drug Conjugate by Combined Ion Activation Methods (vol 92, pg 9790, 2020)
    Watts, Eleanor
    Williams, Jon D.
    Miesbauer, Laura J.
    Bruncko, Milan
    Brodbelt, Jennifer S.
    ANALYTICAL CHEMISTRY, 2020, 92 (17) : 12097 - 12097
  • [46] Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody (vol 89, pg 2024, 1997)
    Hartmann
    BLOOD, 1998, 91 (05) : 1832 - 1832
  • [47] The Anti-CD19 Antibody-Drug Conjugate SAR3419 Prevents Hematolymphoid Relapse Postinduction Therapy in Preclinical Models of Pediatric Acute Lymphoblastic Leukemia (vol 19, pg 1795, 2013)
    Carol, H.
    Szymanska, B.
    Evans, K.
    Boehm, I
    Houghton, P. J.
    Smith, M. A.
    CLINICAL CANCER RESEARCH, 2013, 19 (11) : 3108 - 3108
  • [48] CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy (vol 4, pg 3850, 2020)
    Thapa, B.
    Caimi, P. F.
    Ardeshna, K. M.
    Carlo-Stella, Carmelo
    BLOOD ADVANCES, 2020, 4 (19) : 4606 - 4606
  • [49] Safety and Preliminary Efficacy of F0002, an Anti-CD30 Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Previously Treated with Anti-PD-1 or PD-L1 Therapy: Results from F0002-101 Phase 1 Study
    Song, Yuqin
    Yin, Qingsong
    Li, Zhiming
    Meng, Jingye
    Yan, Yan
    Zhou, Mengli
    Sun, Wenyi
    Liu, Kezhen
    Zhu, Jun
    BLOOD, 2024, 144 : 1674 - 1675
  • [50] SGN-CEACAM5C/SAR445953, a novel topoisomerase I inhibitor antibody-drug conjugate targeting CEACAM5, has potent anti-tumor activity in CRC, PDAC, GC and lung cancer tumor models
    Baudat, Yves
    Nicolazzi, Celine
    Sigurjonsson, Johann Petur
    Amara, Celine
    Clarke, Astrid
    Lyski, Ryan
    Meyer, Dave
    Fantin, Valeria
    Chiron, Marielle
    Decary, Stephanie
    CANCER RESEARCH, 2024, 84 (06)
12345